Fox Run Management’s Karyopharm Therapeutics KPTI Stock Holding History

Fox Run Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,922	Closed	-$98K	–	807
2022 Q4	$98K	Buy	+1,922	New	+$133K	0.04%	563
2022 Q1	–	Sell	-1,030	Closed	-$99K	–	614
2021 Q4	$99K	Buy	+1,030	New	+$103K	0.06%	418
2019 Q1	–	Sell	-1,081	Closed	-$152K	–	590
2018 Q4	$152K	Buy	1,081 +40	+4%	+$6.75K	0.08%	441
2018 Q3	$266K	Buy	+1,041	New	+$288K	0.12%	389
2016 Q1	–	Sell	-1,040	Closed	-$207K	–	489
2015 Q4	$207K	Buy	+1,040	New	+$225K	0.16%	304

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fox Run Management's KPTI Position: Q1 2023 in Review

Fox Run Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 1,922 shares — an estimated $98K sold.

Fox Run Management first reported a position in KPTI in Q4 2015 and held it in 5 quarters. The position peaked at $266K in Q3 2018. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

Fox Run Management reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
Fox Run Management sold 1,922 Karyopharm Therapeutics shares in Q1 2023, an estimated $98K.
Fox Run Management first reported a position in Karyopharm Therapeutics in Q4 2015 and held it in 5 quarters.
Fox Run Management's Karyopharm Therapeutics position peaked at $266K in Q3 2018.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.